Quest Diagnostics (NYSE:DGX) Issues FY 2026 Earnings Guidance

Quest Diagnostics (NYSE:DGX) has issued its FY 2026 earnings guidance, projecting an EPS of 9.45-9.65, which is below the consensus estimate of 10.41. Despite this, the company reported strong Q4 results, beating analyst estimates for both EPS and revenue. Insider selling was noted, but analysts maintain an average “Moderate Buy” rating with a target price of $198.50.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)